Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma

Early results of a prospective phase 2 clinical trial of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance in high-risk smoldering myeloma showed promising results that were previously published. Here, we provide novel insights into the genetic landscape of high-risk...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood Adv
Glavni autori: Mailankody, Sham, Kazandjian, Dickran, Korde, Neha, Roschewski, Mark, Manasanch, Elisabet, Bhutani, Manisha, Tageja, Nishant, Kwok, Mary, Zhang, Yong, Zingone, Adriana, Lamy, Laurence, Costello, Rene, Morrison, Candis, Hultcrantz, Malin, Christofferson, Austin, Washington, Megan, Boateng, Martin, Steinberg, Seth M., Stetler-Stevenson, Maryalice, Figg, William D., Papaemmanuil, Elli, Wilson, Wyndham H., Keats, Jonathan J., Landgren, Ola
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2017
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728141/
https://ncbi.nlm.nih.gov/pubmed/29296837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017005934
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items